Data Sheet | August 27, 2025
NULISAseq™ Mouse Panel 120
Get the Resource
Download NowAs a certified NULISAseq Mouse Panel provider, Sapient can detect and quantify more than 120 cytokines, chemokines, and immune-related and neurology-focused proteins simultaneously, in less than 25 μL of sample input, with this multiplexed assay designed specifically for mouse and murine experiments.
In fact, the NULISAseq Mouse Panel 120, powered by Alamar Biosciences’ NULISA™ technology, offers the most comprehensive coverage of protein biomarkers in mouse models supporting preclinical and translational research, with attomolar sensitivity (fg/ml) to detect even low abundance and difficult-to-measure targets.
From sample processing to data interpretation, Sapient offers end-to-end support to run this panel on our in-house ARGO™ HT instrument and deliver biomarker insights that advance early discovery, preclinical, and translational research across therapeutic areas including autoimmune/inflammation, neurodegeneration, and oncology.
Download the data sheet to learn how the NULISAseq Mouse Panel 120 provides:
- Advanced Multiplexing: to detect 120+ proteins (including neuro-specific targets such as p-tau217) in plasma, serum, and CSF samples using low-input protocols – delivering maximum data from minimal sample.
- High Sensitivity and Detectability: to investigate disease pathophysiology or the efficacy of novel interventions with confidence. The NULISA method leverages a proprietary sequential immunocomplex capture and release mechanism for ultra-high attomolar sensitivity and lower limits of detection across a broad dynamic range.
- Precision in Translational Research: with low intra-plate and inter-plate coefficient of variation (CV), the NULISAseq Mouse Panel delivers reproducible results.
As as an Alamar-certified NULISAseq Mouse Panel provider, you can trust our deep expertise in Alamar’s technologies to deliver robust, reproducible cytokine and chemokine measures. In addition to data generation, we offer data analysis services to interpret and extract actionable insights that advance your study.
Explore how this panel also complements our mass spectrometry-based proteomics services by enabling cross-validation of protein biomarkers discovered in your preclinical studies.